

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

~~CIN- L85191DL2011PLC216530~~ ~~CIN- U85191DL2011PLC216530~~

3rd August, 2018

<p>The Secretary National Stock Exchange of India Ltd Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400051 Trading Symbol: AGLSI.</p>	<p>The Secretary BSE Ltd PhirozeJeejeebhoy Towers, Dalal Street, Mumbai - 400001 Scrip Code:540616</p>
--	--

Sub: Outcome of the Board Meeting held on August 03, 2018

Dear Sir/ Madam,

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 we wish to inform you that Board of Directors of the Company in their meeting held on 03.08.2018 have inter alia, considered and approved the un-audited financial results (standalone & consolidated) for the quarter ended 30th June, 2018 as recommended by Audit Committee.


Pursuant to Regulation 33 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, a copy of duly signed un-audited financial results (standalone & consolidated), along with the Limited Review report by statutory auditor of the Company thereon is enclosed.

The Board Meeting commenced at 05:30 p.m. and concluded at 06:45 p.m.

Please take the above information on your records.

Thanking you
Yours Faithfully

For Artemis Global Life Sciences Limited


Anuj Sood
Company Secretary (A35276)
D-6/10, 3rd Floor, Rana Pratap Bagh
New Delhi-110007

ANAND DUA & ASSOCIATES

Chartered Accountants

Flat No 11, Pocket-7, Sector-12,

Dwarka, New Delhi-110 078

Ph: 47021279

Review report

To

The Board of Directors

Artemis Global Life Sciences Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results (the Statement') of Artemis Global Life Sciences Limited ('the Company') and its subsidiaries (the Company and its subsidiaries constitute 'the Group') for the quarter ended 30 June 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 3rd August, 2018. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the Company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. We did not review the interim financial results of the subsidiaries included in the Statement whose interim financial results reflect the Group's share in the profit before tax is Rs 603.96 lakhs for the quarter ended 30th June 2018, and the Group's share in the profit after tax of Rs 371.30 lakhs for the quarter ended 30th June 2018 as considered in the Statement of the Group. These financial results have been reviewed by other auditors whose report has been furnished to us by the Management. Our report on the Statement of the Group, in so far as it related to the amounts and disclosures included in respect of the subsidiaries, is based solely on the reports of the other auditors.
5. Based on our review conducted as mentioned in paragraphs 3 and 4 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.


Place: New Delhi

Dated: 03.08.2018

For Anand Dua & Associates

Chartered Accountants

FRN: 04263N



(Anand Dua) Partner

M.No. 083503

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN: U85191DL2011PLC216530 CIN- L85191DL2011PLC216530

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018

(₹ in Lacs)

S No.	Particulars	Quarter ended			year ended
		30-Jun-18 (Unaudited)	31-Mar-18 (Audited) (Refer Note 6)	30-Jun-17 (Unaudited)	31-Mar-18 (Audited)
1	Revenue from operations	10.20	10.20	10.20	40.80
2	Other income	-	-	19.23	-
3	Total Income	10.20	10.20	29.43	40.80
	Expenses				
	Purchases of pharmacy drugs & medical consumables	-	-	-	-
	Purchases of Stock in Trade	-	-	-	-
	Changes in inventories of pharmacy drugs, Medical consumables & Stock in Trade	-	-	-	-
	Employee Benefits expenses	6.15	4.21	3.73	15.45
	Finance costs	-	-	-	-
	Depreciation and amortization expense	3.76	3.72	3.41	14.74
	Other expenses	8.23	8.51	9.99	37.43
4	Total expenses	18.14	16.44	17.13	67.62
5	Profit/(Loss) before Tax and exceptional items	(7.94)	(6.24)	12.30	(26.82)
6	Exceptional Items	-	0.39	-	10.99
7	Profit before tax	(7.94)	(5.85)	12.30	(37.81)
8	Tax Expense				
	Current Tax	-	0.73	2.37	2.99
	Deferred tax	(2.07)	10.93	0.96	(10.92)
	Total tax expense	(2.07)	11.66	3.33	(7.93)
9	Profit for the period	(5.87)	(17.51)	8.97	(29.88)
10	Other comprehensive income				
I	Items that will not be reclassified to profit or loss				
a	gains / (losses) on defined benefit plans	-	-	-	-
b	Deferred tax adjustment on revaluation	-	-	-	-
c	Income tax relating to items that will not be reclassified to profit & loss	-	-	-	-
II	Net other comprehensive income not to be reclassified to profit or loss in subsequent periods:	-	-	-	-
	Other comprehensive income for the period, net of income tax	-	-	-	-
11	Total comprehensive income/(loss) ('OCI')	(5.87)	(17.51)	8.97	(29.88)
12	Paid up equity share capital (Face value Rs. 2/- each)	1,323.77	1,323.77	1,323.77	1,323.77
13	Other equity excluding revaluation reserve (as per balance sheet of previous accounting year)	-	-	-	14,529.92
14	Earning per share (Face value Rs. 2/- each) (refer note 7)				
	Basic (Rs.)	(0.01)	(0.03)	0.01	(0.05)
	Diluted (Rs.)	(0.01)	(0.03)	0.01	(0.05)



De

Notes

1. The above results for the quarter ended June 30, 2018 were reviewed by the Audit Committee & approved by the Board of Directors at their respective meetings held on August 3rd, 2018. The statutory auditors have expressed unmodified opinion on the aforesaid results.
2. Adoption of Ind AS 115-Revenue from contracts with customers
The Ministry of Corporate affairs (MCA), on March 20th, 2018 notified Ind AS 115 "Revenue from Contracts with Customers" as part of Companies (Indian Accounting Standards) Amendment Rules 2018. The new standard is effective from April 1, 2018. The adoption of Ind AS - 115 by the company effective 1st April, 2018 has no significant impact on the financial results for the quarter ended 30th June, 2018.
3. The Company's operation predominantly comprise of only one segment - income from lease of medical equipments to Artemis Medicare Services Ltd. and therefore the figures shown above relate to that segment.
4. The Company and its subsidiary company i.e. Artemis Health Sciences Ltd and its step subsidiary companies i.e. Athena Eduspark Limited and Artemis Medicare Services Limited have decided to merge and the proposed Composite Scheme of Amalgamation between the aforesaid Companies and their respective shareholders and creditors under section 230 to 232 and other applicable provisions of Companies Act, have been approved in the meeting of the Board of Directors held on 09th May, 2018 and this is subject to clearance by National Company Law Tribunal & other regulatory approvals.
5. The above financial results have been prepared in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under 133 of the companies act 2013, and the other recognised accounting practices and policies to the extent applicable
6. The figures of the quarter ended March 31st, 2018 are balancing figures between the full financial year ended March 31st, 2018 and unaudited published year to date figures in respect of the quarter ended December 31st, 2017, which was subject to limited review.
7. EPS is not annualised for the quarter ended June 30, 2018, quarter ended March 31, 2018 & quarter ended June 30, 2017.
8. Previous period figures have been regrouped / reclassified wherever necessary to correspond with the current period classification / disclosures.



PLACE: GURUGRAM
DATE: AUGUST 3, 2018

For and on behalf of the Board of Directors of
ARTEMIS GLOBAL LIFE SCIENCES LIMITED

A handwritten signature in black ink, appearing to read "Onkar S. Kanwar".

ONKAR S. KANWAR
CHAIRMAN

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN- L85191DL2011PLC216530 ~~CIN: U85191DL2011PLC216530~~

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018

(₹ In Lacs)

S. No.	Particulars	Quarter ended			year ended
		30-Jun-18 (Unaudited)	31-Mar-18 (Audited) (Refer Note 6)	30-Jun-17 (Unaudited)	31-Mar-18 (Audited)
1	Revenue from operations	12,643.07	13,733.45	11,930.26	50,278.71
2	Other income	116.86	105.29	112.85	429.90
3	Total Income	12,759.94	13,838.74	12,043.11	50,708.60
	Expenses				
	Purchases of pharmacy drugs & medical consumables	2,991.29	2,922.06	3,444.58	12,083.89
	Purchases of Stock in Trade	28.62	42.78	46.35	137.15
	Changes in inventories of pharmacy drugs, Medical consumables & Stock in Trade	10.66	38.26	(509.26)	(8.31)
	Employee benefit expenses	2,356.49	2,297.88	2,239.45	9,068.24
	Finance costs	202.94	258.74	206.80	942.03
	Depreciation and amortization expense	490.25	474.15	435.48	1,880.56
	Other expenses	6,083.66	5,875.01	5,660.63	23,103.62
4	Total expenses	12,163.92	11,908.88	11,524.03	47,207.18
5	Profit/(Loss) before Tax and exceptional items	596.02	1,929.86	519.08	3,501.42
6	Exceptional Items	-	(0.39)	-	10.99
7	Profit before tax	596.02	1,930.25	519.08	3,490.43
8	Tax Expense				
	Current Tax	259.14	328.47	116.61	656.31
	Deferred Tax	(28.55)	4.41	78.96	206.49
	Total Tax Expense	230.59	332.88	195.57	862.80
9	Profit for the period	365.43	1,597.37	323.51	2,627.63
10	Other comprehensive income				
I	Items that will not be reclassified to profit or loss				
a	gains / (losses) on defined benefit plans	(4.39)	(5.05)	(4.17)	(17.56)
b	Deferred tax adjustment on revaluation	6.78	14.30	-	14.30
c	Income tax relating to items that will not be reclassified to profit & loss	1.53	1.76	1.46	6.14
II	Net other comprehensive income not to be reclassified to profit or loss in subsequent periods:	3.92	11.01	(2.71)	2.88
	Other comprehensive income for the period, net of income tax	3.92	11.01	(2.71)	2.88
11	Total comprehensive income/(loss) ('OCI')	369.35	1,608.38	320.80	2,630.50
12	Paid up equity share capital (Face value Rs. 2/- each)	1,323.77	1,323.77	1,323.77	1,323.77
13	Other equity excluding revaluation reserve (as per balance sheet of previous accounting year)	-	-	-	19,442.49
14	Earning per share (Face value Rs. 2/- each) (refer note 7)				
	Basic (Rs.)	0.55	2.41	0.49	3.97
	Diluted (Rs.)	0.55	2.41	0.49	3.97



OK

Corporate Off : SF 202, Peach Tree, C-Block, Sushant Lok-1, Gurgaon-122002

Website : www.aglsl.in • E-mail : investor@aglsl.in • Tel. 0124 - 4262305/07 • Fax : 0124 - 4262306

Notes

1. The above results for the quarter ended June 30, 2018 were reviewed by the Audit Committee & approved by the Board of Directors at its meeting held on August 3rd, 2018. The statutory auditors have expressed unmodified opinion on the aforesaid results.

2. Adoption of Ind AS 115-"Revenue from Contracts with Customers"

The Ministry of Corporate affairs (MCA), on March 20th, 2018 notified Ind AS 115 "Revenue from Contracts with Customers" as part of Companies (Indian Accounting Standards) Amendment Rules 2018. The new standard is effective from April 1, 2018. The adoption of Ind AS - 115 by the company effective 1st April, 2018 has no significant impact on the financial results for the quarter ended 30th June, 2018.

3. Segment Reporting

Business segment

The company's operation predominantly comprise of only one business segment- Income from Healthcare services.

Geographical information

Geographical information analyses the company's revenue by the Company's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

Region	Quarter ended		Year ended	
	30-Jun-18	31-Mar-18	30-Jun-17	31-Mar-18
India	7,760.80	8,798.82	7,654.16	32,367.91
Outside India	4,882.27	4,934.63	4,276.10	17,910.80
Total	12,643.07	13,733.45	11,930.26	50,278.71

4. The Company and its subsidiary company i.e. Artemis Health Sciences Ltd and its step subsidiary companies i.e. Athena Eduspark Limited and Artemis Medicare Services Limited have decided to merge and the proposed Composite Scheme of Amalgamation between the aforesaid Companies and their respective shareholders and creditors under section 230 to 232 and other applicable provisions of Companies Act 2013, have been approved in the meeting of the Board of Directors held on 09th May, 2018 and this is subject to clearance by National Company Law Tribunal & other regulatory approvals.

5. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.

6. The figures of the quarter ended March 31st, 2018 are balancing figures between the audited figures in respect of the full financial year ended March 31st, 2018 and unaudited published year to date figures upto the third quarter ended December 31st, 2017, which was subject to limited review.

7. EPS is not annualised for the quarter ended June 30, 2018, quarter ended March 31, 2018 & quarter ended June 30, 2017.

8. Previous period figures have been regrouped / reclassified wherever necessary to correspond with the current period classification / disclosures.



PLACE: GURUGRAM
DATE: AUGUST 3, 2018

For and on behalf of the Board of Directors of
ARTEMIS GLOBAL LIFE SCIENCES LIMITED

Onkar S. Kanwar

ONKAR S. KANWAR
CHAIRMAN